Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin, Carfilzomib, Lenalidomide, and Dexamethasone in Multiple Myeloma
NCT04822337Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2021
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Started May 2021; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04822337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822337.